N/A
N=34
Effect of Whole Fruit on Glycemic Control in Adults With Type 2 Diabetes
Diabetes Mellitus, Type 2
Bottom Line
View on ClinicalTrials.gov: NCT03758742 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Diabetes Remission Rate — 3; 6 Participants — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- High-Fruit Diet (Behavioral)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- University of Alabama at Birmingham
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Diabetes Remission Rate |
3; 6 | <0.0001 sig |
| PRIMARY Medication Effect Score (MES) |
-0.5 | — |
| PRIMARY Mean Glucose During a 3-hour Oral Glucose Tolerance Test (OGTT) |
11; -20 | — |
| PRIMARY Mean 24-hour Glucose Levels as Measured by Continuous Glucose Monitoring (CGM), Adjusted for Any Changes in Medication Doses Via the MES |
-12; -18 | — |
| SECONDARY Insulin Sensitivity |
1.27; 3.03 | — |
| SECONDARY Dynamic Beta-Cell Responsivity |
135; 122 | — |
| SECONDARY Static Beta-Cell Responsivity |
-3.0; 0.9 | — |
| SECONDARY Mean Insulin During a 3-hour OGTT |
-17.1; -38.1 | — |
| SECONDARY Mean C-peptide During a 3-hour OGTT |
-0.4; -1.7 | — |
| SECONDARY Mean Amplitude of Glycemic Excursions From CGM |
— | — |
| SECONDARY Fasting Glucose |
— | — |
| SECONDARY HbA1c |
— | — |
| SECONDARY Liver Fat (Intrahepatic Lipid) |
— | — |
| SECONDARY Pancreatic Fat |
— | — |
| SECONDARY Systolic and Diastolic Blood Pressure |
— | — |
| SECONDARY Heart Rate |
— | — |
| SECONDARY Time-in-range Metrics From CGM |
— | — |
| SECONDARY Lipids |
— | — |
Summary
Diabetes costs the U.S. healthcare system more than any other disease, and nearly half of Americans will develop either diabetes or prediabetes in their lifetime. It is therefore critical to find new strategies to treat or reverse diabetes.
One such approach is adopting a healthy diet, which can dramatically improve blood sugar levels in adults with type 2 diabetes and even induce diabetes remission. Despite this, not much is known about which food groups are most effective at improving blood sugar levels in patients with diabetes.
Interestingly, of the various food groups, epidemiologic data suggests that whole fruit may be one of the most efficacious at both preventing type 2 diabetes and improving blood sugar in patients with type 2 diabetes. However, few clinical trials have investigated the effects of whole fruit on blood sugar control. This study will therefore be the first to determine the effects of increasing whole fruit as a food group in type 2 diabetes patients. This supervised controlled feeding trial will test whether consuming a diet rich in whole fruit for 12 weeks can improve glycemic control and cardiometabolic health in weight-stable adults with type 2 diabetes. The primary endpoint is glycemic control. Since changes in medication doses can skew the interpretation of glycemic outcomes, glycemic control will be assessed hierarchically (in descending order of importance) using (a) attainment of nondiabetic glycemia without medications (as a proxy for diabetes remission), (b) medication effect scores, (c) mean glucose during an oral glucose tolerance test, and (d) 24-hour mean glucose from continuous glucose monitoring. As secondary aims, this study will also test whether consuming a large amount of fructose in whole food form affects liver fat, pancreatic fat, and cardiovascular disease risk factors.
Eligibility Criteria
Inclusion Criteria
- 20-70 years old
- BMI ≤45.0 kg/m^2
- First diagnosed with type 2 diabetes within the past 6 years
- HbA1c between 6.0-9.5%%
Exclusion Criteria
- On insulin
- Diagnosis of diabetes before age 18
- Estimated glomerular filtration rate < 45 ml/min per 1.732 m^2
- Heart attack in the past 6 months or severe or unstable heart failure
- On weight loss medication
- Change in the dosage of a chronic medication that may affect study endpoints within the past 3 months
- Clinically significant laboratory abnormality (e.g. abnormal hemoglobin levels)
- Significant gastrointestinal disease, major gastrointestinal surgery, or gallstones
- Significant cardiovascular, renal, cardiac, liver, lung, adrenal, or nervous system disease that might compromise safety or data validity
- Evidence of cancer (other than non-melanoma skin cancer) within the last 5 years
- Lost or gained more than 5 kg of weight in the past 6 months
- Pregnant, planning to become pregnant in the next 12 months, or breastfeeding
- Major psychiatric condition that would affect the ability to participate in the study
- Not able to eat the provided study meals
- Behavioral factors or circumstances that may impede adhering to the dietary intervention
- Not able to do the MRI/MRS abdominal scan, such as due to claustrophobia, implanted metal objects, or a body girth of 60 cm or greater
Data sourced from ClinicalTrials.gov (NCT03758742). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.